In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.52, marking a +2.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.54% ...

Back in high school chemistry, I remember waiting with my bench partner for crystals to form on our stick in the cup of blue ...

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the ...

Next steps Recursion intends to submit these data for publication in a peer reviewed scientific journal. Next steps will be guided by regulatory discussions and on-going long term extension study.

Recursion is a powerful technique used to solve problems with repeating patterns, and is a fundamental structure in software. To date there is no known general way to apply a recursive solution to ...

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Read more here.

Recursion uses a data-driven approach to drug discovery, launching four clinical trials in 2021 and planning a fifth in oncology. Click here to read more.